about
Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymesGlucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complexRecent advances in the in silico modelling of UDP glucuronosyltransferase substrates.Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidationGenetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.Regulation of UDP glucuronosyltransferase genes.Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches.Glucuronidation and the UDP-glucuronosyltransferases in health and disease.S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.Regulation of UDP glucuronosyltransferases in the gastrointestinal tract.Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltransferases.Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.Expression of androgen receptor splice variants in clinical breast cancers.Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression.UGT3A: novel UDP-glycosyltransferases of the UGT superfamily.Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2-8) in Normal and Cancerous Breast and Prostate Cells.Transcriptional regulation of human UDP-glucuronosyltransferase genes.Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway.Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2.Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region.Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells.Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2.Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells.A novel function for UDP glycosyltransferase 8: galactosidation of bile acids.Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.Advances in drug metabolism and pharmacogenetics research in Australia.Introduction of an N-Glycosylation Site into UDP-Glucuronosyltransferase 2B3 Alters Its Sensitivity to Cytochrome P450 3A1-Dependent ModulationHomodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling.Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase.The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates.Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways.Inhibitory effects of adenine nucleotides and related substances on UDP-glucuronosyltransferase: structure-effect relationships and evidence for an allosteric mechanism.
P50
Q24336118-FBC8E1CE-D693-46F4-86DD-221A7446A67AQ28203020-EDA65633-2E99-4FBB-92CC-C2052413B984Q28580516-9F61A1CD-EAE7-4F50-A916-F6C7242C6879Q30367367-856F2A60-166D-4F1D-B146-4F72D82C5BBCQ31034463-1F47B5C4-B9E5-49EA-BCCB-A9EC78127BF9Q35035611-13C218DE-08BC-4F09-BBBC-19D896C2FE54Q35137540-0B97C17E-7A09-4390-B90E-1E280BF347E3Q35639092-4A93758E-9D39-4077-A25D-67DBB63A9C59Q35672985-3357A77C-4A84-480A-823C-D87BAA23999BQ35826926-564BDA00-9F53-4186-9476-DCC38183C8ADQ35886045-DE1D35C7-D3B0-48ED-AA53-05AE37D07379Q36175555-C98F0D98-9896-421C-84C6-E11F88B38B79Q36214191-8B401028-21B0-4040-90CF-45CFF96EFE02Q36689084-3CFF7003-E1D1-4E41-B0E7-252CBEEA3695Q37120639-A5777E4A-EEA6-4934-9557-AF6354B709D4Q37611031-E5C520C5-3F3B-4D6F-A745-8A857A80364BQ37631437-D6CF902B-DACD-4600-8F24-117D25A189CAQ38261875-0DA0C392-12EF-417E-9AB8-1726CB176A15Q38308097-F9F37D47-9F0F-4ED0-A936-652882D453EAQ38441033-58D3D4EB-3615-4B21-AA1A-DE54ADA817E7Q38707922-A3C9EEA2-74E6-4F61-B980-753172C18D39Q38717288-7A200355-B102-43DC-A1A8-FE4EA515349FQ38753546-E859E4C1-A5DB-40D9-A809-E7366361DEDEQ38846244-C5213F21-6A7C-4EA2-AEB1-CBBA05FEE01CQ38847188-D19B19E9-1114-403E-B14F-9C996144E79BQ38864841-31357390-9CDA-4915-8EB3-3BB5B9DEFC30Q38906270-791ADFEA-7C4D-4FC9-8059-6D39A624DB39Q38927567-E27CF1F8-0472-4458-A1E7-508977FC08BDQ39020826-2600CAD5-E3FD-44C5-874B-CEC768C42F7EQ39033152-04F64D3E-FCDD-4D29-AF73-208974658EFBQ39036746-EDE696A3-C5D2-41E6-AEDE-8629BD149222Q39147167-4C360B63-2BDF-4D1E-A2FA-EA2432746C6DQ39471802-11172700-35EF-4C81-A9E3-BED23E7A7F11Q39663744-FBBDDF14-A229-406E-9985-641F5DA805E4Q39680659-9D7CD4AE-28EC-4E1E-9722-C62B82ECFFFFQ39921876-274FDCE4-012B-444A-82E2-AB8F4396408FQ39999160-E60317EE-620B-4DC9-8A01-699AA1B0204BQ40051628-633BAD44-4A7F-4FCC-BB7E-3C15C81CAEEAQ40078598-7466B4DF-37B5-42C4-96EC-FF6CC03F5D2AQ40086385-9CD9B07F-870C-42F1-8681-FD0F1ECA995F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Peter I Mackenzie
@ast
Peter I Mackenzie
@en
Peter I Mackenzie
@es
Peter I Mackenzie
@nl
Peter I Mackenzie
@sl
type
label
Peter I Mackenzie
@ast
Peter I Mackenzie
@en
Peter I Mackenzie
@es
Peter I Mackenzie
@nl
Peter I Mackenzie
@sl
prefLabel
Peter I Mackenzie
@ast
Peter I Mackenzie
@en
Peter I Mackenzie
@es
Peter I Mackenzie
@nl
Peter I Mackenzie
@sl
P106
P21
P31
P496
0000-0002-0697-6878